These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 30946963)
1. The impact of patients' real-life environmental temperature and humidity use conditions of tiotropium dry powder inhaler on its aerosol emission characteristics. Ammari WG; Mohammad MK; Tayyem RF Eur J Pharm Sci; 2019 May; 133():137-144. PubMed ID: 30946963 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of patients' real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition. Ammari WG; Khalil Mohammad M; Tayyem RF Pulm Pharmacol Ther; 2019 Oct; 58():101829. PubMed ID: 31352077 [TBL] [Abstract][Full Text] [Related]
3. Delivered Lung Dose and Aerodynamic Particle Size Distribution of Salbutamol Pressurized Metered Dose Inhaler After Living Under Patients' Realistic Retention Environments. Ammari WG; Khalil Mohammad M; Tayyem RF; Martin GP; Royall PG J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):386-395. PubMed ID: 31199708 [No Abstract] [Full Text] [Related]
4. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Chapman KR; Fogarty CM; Peckitt C; Lassen C; Jadayel D; Dederichs J; Dalvi M; Kramer B Int J Chron Obstruct Pulmon Dis; 2011; 6():353-63. PubMed ID: 21760722 [TBL] [Abstract][Full Text] [Related]
5. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. Janson C; Lööf T; Telg G; Stratelis G; Nilsson F NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177 [TBL] [Abstract][Full Text] [Related]
6. Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler. Perry J; Trautman B; Takher-Smith J; Kramer S; Kane K; Silverman M; Tan L; Haughie S; Richter W; Kirkov V; Arsova S; Ward J; Hava DL Br J Clin Pharmacol; 2019 Mar; 85(3):580-589. PubMed ID: 30521129 [TBL] [Abstract][Full Text] [Related]
7. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI). Mohan M; Lee S; Guo C; Peri SP; Doub WH AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069 [TBL] [Abstract][Full Text] [Related]
9. The clinical relevance of dry powder inhaler performance for drug delivery. Demoly P; Hagedoorn P; de Boer AH; Frijlink HW Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253 [TBL] [Abstract][Full Text] [Related]
10. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Young PM; Sung A; Traini D; Kwok P; Chiou H; Chan HK Pharm Res; 2007 May; 24(5):963-70. PubMed ID: 17377746 [TBL] [Abstract][Full Text] [Related]
11. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers. Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622 [TBL] [Abstract][Full Text] [Related]
12. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
14. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™). Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465 [TBL] [Abstract][Full Text] [Related]
15. Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols. Yu J; Wong J; Ukkonen A; Kannosto J; Chan HK Pharm Res; 2017 Aug; 34(8):1707-1715. PubMed ID: 28540500 [TBL] [Abstract][Full Text] [Related]
16. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair Yildiz P; Bayraktaroglu M; Gorgun D; Secik F Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513 [TBL] [Abstract][Full Text] [Related]
17. An Exploration of Factors Affecting Ruzycki CA; Martin AR; Finlay WH J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632 [No Abstract] [Full Text] [Related]